Our Philosophy
- Strategic: Create options for the corporation to expand into new therapeutic approaches and businesses
- Add value: Help innovators develop their concept from idea to Proof of Concept
- Secure financial return to support continuity → Evergreen Fund Model
What do we bring into the partnership with our portfolio companies?
- Boehringer Ingelheim has built a strong pipeline based on in-house R&D
- Our Investment Professionals have a hands-on-mentality and strong background in the pharma industry
- Upon request, we can provide scientific, managerial, and commercial support
- Since we have no fund-life-time, we can support our portfolio companies from company creation up to exit - which is our preferred model
Our Focus
- Immunomodulation, esp. Immuno-Oncology
- Tissue Regeneration, e.g. stem cells, NCEs, biologics
- New Therapeutic Modalities, e.g. genetherapy, cell-based therapeutics
- Microbiome, esp. approaches based on NCEs and biologics
- Antiinfectives with new mechanism of action
- Patients Care Management, e.g. diagnosis and monitoring of disease, prevention of onset and progression of disease (incl. digital biomarkers), population management
- Medication adherence
- Digital companion therapy
- Digital therapy as stand-alone
Fund Volume
- Total fund volume: €300 million (€250 million for Therapeutics and €50 million for Digital Health)
- Initial investment at an early stage of company's life
- Follow-on investments in pace with the company's progress
- Staged investments of up to €15 million over company's lifetime (up to €7.5 million for Digital Health companies)
Why Boehringer Ingelheim?
- Strategic orientation: Long-term view
- Family owned: Continuity, Cultural Identity
- No option required, no strings attached: Openness to syndicate with corporate VCs and institutional VCs
- Successful track record in R&D: Able and willing to provide scientific, managerial and commercial support
- Help positioning portfolio companies for an exit
